LIPOSYN II 20% Drug Patent Profile
✉ Email this page to a colleague
When do Liposyn Ii 20% patents expire, and when can generic versions of Liposyn Ii 20% launch?
Liposyn Ii 20% is a drug marketed by Hospira and is included in one NDA.
The generic ingredient in LIPOSYN II 20% is safflower oil; soybean oil. There are three drug master file entries for this compound. Additional details are available on the safflower oil; soybean oil profile page.
Summary for LIPOSYN II 20%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 4 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | LIPOSYN II 20% at DailyMed |
Recent Clinical Trials for LIPOSYN II 20%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pennington Biomedical Research Center | Early Phase 1 |
| The Cleveland Clinic | Early Phase 1 |
| The University of Texas Health Science Center at San Antonio | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for LIPOSYN II 20%
US Patents and Regulatory Information for LIPOSYN II 20%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | LIPOSYN II 20% | safflower oil; soybean oil | INJECTABLE;INJECTION | 018991-001 | Aug 27, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
